Alcon, Inc. (ALC)
| Market Cap | 31.61B |
| Revenue (ttm) | 7.51B |
| Net Income (ttm) | -656.00M |
| Shares Out | 488.20M |
| EPS (ttm) | -1.47 |
| PE Ratio | n/a |
| Forward PE | 33.22 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $70.17 |
| Previous Close | $69.69 |
| Change ($) | 0.48 |
| Change (%) | 0.69% |
| Day's Open | - |
| Day's Range | 69.65 - 70.64 |
| Day's Volume | 0 |
| 52-Week Range | 39.86 - 70.64 |
Alcon, Inc. (ALC) Presents at JPMorgan Healthcare Conference - (Transcript)
Eye-care devices market is an attractive end-market supported by secular growth trends such as aging population, increased myopia prevalence, and innovation in products leading to better outco...
Alcon, Inc. (ALC) CEO David Endicott on Q3 2020 Results - Earnings Call Transcript
Unable to provide full-year guidance due to difficult market conditions, Alcon CEO says
Alcon CEO David Endicott discusses the company's third-quarter earnings.
Shares of Alcon (NYSE:ALC) rose 2.73% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share decreased 15.22% year over year to $0.39, which beat t...
Alcon Inc. (ALC) CEO David Endicott on Q2 2020 Results - Earnings Call Transcript
Alcon Inc. (ALC) CEO David Endicott on Q1 2020 Results - Earnings Call Transcript
Alcon, Inc. (ALC) CEO David Endicott on Q4 2019 Results - Earnings Call Transcript
The switch will increase the availability of pain and allergy drugs from GlaxoSmithKline and Alcon.
About ALC
Alcon, an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients. It operates through two segments, Surgical and Vision Care. The Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures, such as cataracts, vitreoretinal, refractive laser, and... [Read more...]
| Industry Medical Instruments & Supplies | Founded 1945 |
| CEO David J. Endicott | Employees 20,000 |
| Stock Exchange NYSE | Ticker Symbol ALC |
Financial Performance
In 2019, Alcon's revenue was $7.51 billion, an increase of 4.96% compared to the previous year's $7.15 billion. Losses were -$656.00 million, 189.0% more than in 2018.
Analyst Forecasts
The average 12-month stock price forecast for Alcon is 68.00, which is a decrease of -3.09% from the latest price.